The global point-of-care (POC) molecular diagnostics market size was estimated at USD 8.22 billion in 2024 and is projected to reach USD 14.47 billion by 2033, growing at a CAGR of 6.52% from 2025 to 2033. This market primarily focuses on delivering rapid and highly accurate molecular testing directly near the patient, enabling quicker clinical decision-making and improved treatment outcomes. These diagnostic platforms are widely used across various applications, including the detection of infectious diseases, respiratory illnesses, and sexually transmitted infections, where timely and precise results are critical for effective patient management.
The market’s growth is strongly driven by the increasing demand for decentralized testing solutions, particularly in resource-limited settings, rural areas, and emergency care environments. The growing global burden of infectious diseases and the urgent need for rapid turnaround times have further fueled the adoption of point-of-care molecular diagnostic technologies. Continuous technological advancements in areas such as microfluidics, isothermal amplification, and portable PCR systems have significantly improved the accuracy, efficiency, and accessibility of these diagnostic tools. Additionally, the post-pandemic focus on strengthening healthcare systems and ensuring rapid disease response capabilities continues to support market expansion.
In primary care settings, point-of-care molecular diagnostics now encompass a wide range of tests—from basic glucose monitoring to more complex coagulation and infection detection tests. Many healthcare professionals and clinics are transitioning from traditional centralized laboratory testing to POC solutions, as these methods eliminate delays associated with specimen transportation and preparation. This shift enables faster clinical decisions and improved patient flow.
Key benefits of point-of-care molecular diagnostics include the rapid availability of test results, lower operational costs, and improved clinical outcomes. The industry has witnessed rapid growth in recent years, particularly across the U.S. and European countries, driven by rising awareness of the medical, operational, and economic benefits of POC testing. Healthcare providers are increasingly recognizing the value of these technologies in enhancing diagnostic efficiency, optimizing patient care, and reducing the overall burden on centralized laboratories.
Key Market Trends & Insights:
• The North America point-of-care molecular diagnostics market accounted for the largest revenue share of 45.70% in 2024, reflecting the region’s strong adoption of advanced diagnostic technologies and well-established healthcare infrastructure. The U.S. led the North American market, holding the highest revenue share in 2024, driven by the widespread implementation of rapid testing solutions, continuous technological innovation, and growing awareness of the benefits of decentralized diagnostics.
• Based on test location, the over-the-counter (OTC) segment dominated the global market with the largest revenue share of 52.60% in 2024. This dominance is primarily due to the rising demand for at-home testing kits and consumer-friendly diagnostic tools that allow individuals to perform tests conveniently and obtain quick results without visiting healthcare facilities.
• In terms of application, the infectious disease segment held the largest revenue share of 47.95% in 2024. The high prevalence of infectious diseases, such as respiratory infections, influenza, and sexually transmitted infections, has significantly contributed to the increased adoption of point-of-care molecular diagnostics, enabling early detection and effective disease management.
• Based on technology, the PCR-based segment dominated the market with the largest revenue share of 66.37% in 2024. Polymerase Chain Reaction (PCR) technology remains the gold standard in molecular diagnostics due to its high sensitivity, specificity, and ability to deliver accurate results within a short time frame. The continuous advancements in portable and real-time PCR systems have further supported the widespread use of this technology in both clinical and non-clinical settings.
• Based on end use, the decentralized labs segment held the largest revenue share of 42.74% in 2024. The growing preference for decentralized testing models, which allow faster diagnosis and reduce patient waiting times, has driven this segment’s growth. These labs play a crucial role in expanding access to molecular diagnostics, particularly in remote and resource-limited regions, while ensuring timely clinical decision-making and improved patient outcomes.
Order a free sample PDF of the Point Of Care Molecular Diagnostics Market Intelligence Study, published by Grand View Research.
Market Size & Forecast:
• 2024 Market Size: USD 8.22 Billion
• 2033 Projected Market Size: USD 14.47 Billion
• CAGR (2025-2033): 6.52%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market
Key Companies & Market Share Insights:
Key players in the point-of-care molecular diagnostics industry are actively emphasizing innovation through the development of new products and the pursuit of regulatory approvals to broaden their product portfolios. These companies are continuously investing in research and development to introduce advanced diagnostic solutions that offer higher accuracy, faster results, and improved usability for healthcare professionals and patients alike.
In addition to product innovation, market participants are implementing strategic initiatives such as partnerships, collaborations, mergers, and acquisitions to strengthen their overall market position. Such alliances enable companies to combine technological expertise, expand distribution networks, and gain access to new markets. These collaborative efforts also facilitate the sharing of resources, technical know-how, and regional expertise, ultimately driving the wider adoption of point-of-care molecular diagnostics.
Through these initiatives, companies aim to enhance their technological capabilities, extend their geographic footprint, and improve the accessibility of rapid diagnostic solutions across various healthcare settings—including hospitals, clinics, decentralized labs, and home-care environments. Collectively, these strategies are helping industry players address the growing global demand for fast, reliable, and efficient molecular testing solutions.
Key Players
• Abbott
• Bayer AG
• F. Hoffmann-La Roche AG
• Nova Biomedical
• QIAGEN
• Nipro Diagnostics
• Danaher
• Bio-Rad Laboratories, Inc.
• bioMérieux
• Agilent Technologies, Inc.
• Abaxis
• OraSure Technologies
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
The point-of-care molecular diagnostics market is on a solid growth trajectory, driven by the increasing need for rapid, near-patient testing in infectious diseases and other critical applications. Technological advancements (such as portable PCR and microfluidics), expanding use in decentralized and home-care settings, and the shift toward decentralized healthcare delivery are key enablers. The market outlook is positive for companies that can deliver user-friendly, accurate, and cost-effective molecular diagnostic solutions.
